世界中医药2025，Vol.20Issue(2)：275-282,8.DOI:10.3969/j.issn.1673-7202.2025.02.013
含砷中药复方为主治疗高危骨髓增生异常综合征不良因素探析
Adverse Factors in the Treatment of High-risk MDS with Arsenic-containing Chinese Medicine Compound Formulas
摘要
Abstract
Objective:To investigate the adverse factors affecting the efficacy of arsenic-containing Chinese medicine compound formulas in the treatment of high-risk myelodysplastic syndrome(HR-MDS)and to identify predictive indicators of poor efficacy.Methods:A retrospective analysis was conducted on the clinical data of 200 HR-MDS patients diagnosed at Xiyuan Hospital,China Academy of Chinese Medical Sciences,between January 2016 and September 2022.Data included general patient information,rou-tine blood tests,bone marrow smears,histopathology,and cytogenetics.Results:Age≥ 60 years(P=0.015),platelet count＜50 × 109/L(P=0.003),and progression to MDS-AML(P=0.008)were identified as adverse factors affecting the efficacy of arsenic-containing Chinese medicine compound formulas combined with hypomethylating agents(HMAs)or androgens for HR-MDS treat-ment.Furthermore,age ≥ 60 years(P=0.012),platelet count＜50 × 109/L(P=0.004),and MDS progression to AML(MDS-AML)(P=0.008)were independent risk factors for poor efficacy in this treatment regimen.For patients receiving arsenic-contai-ning Chinese medicine compound formulas combined with HMAs,MDS-AML(P=0.011)and chemotherapy cycles＜5(P=0.024)were adverse factors,while MDS-AML proportion(P=0.048)was identified as an independent risk factor for poor effica-cy.For patients treated with arsenic-containing Chinese medicine compound formulas combined with androgens,age≥60 years(P=0.013),platelet count≥50 × 109/L(P=0.019),and MDS-AML(P=0.034)were adverse factors.Additionally,age ≥ 60 years(P=0.019),platelet count＜50 × 109/L(P=0.04),and MDS-AML(P=0.041)were independent risk factors for poor effi-cacy in this treatment group.Conclusion:MDS-AML and chemotherapy cycles＜5 can be considered as indicators of poor efficacy for arsenic-containing Chinese medicine compound formulas combined with HMAs in HR-MDS treatment.Additionally,age ≥ 60 years,platelet count＜50 × 109/L,and MDS-AML are indicators of poor efficacy when arsenic-containing Chinese medicine com-pound formulas are combined with androgen therapy.关键词
高危骨髓增生异常综合征/血液疾病/含砷中药复方/去甲基化药物/雄激素/疗效分析/预测指标/不良因素Key words
High-risk myelodysplastic syndrome/Blood disorders/Arsenic-containing Chinese medicine compound formulas/Hy-pomethylating agents/Androgens/Efficacy analysis/Predictive indicators/Adverse factors分类
中医学引用本文复制引用
靳楠,毛悦,吕妍,陈卓,王德秀,刘为易,刘驰,唐旭东..含砷中药复方为主治疗高危骨髓增生异常综合征不良因素探析[J].世界中医药,2025,20(2):275-282,8.基金项目
国家自然科学基金面上项目(82074258,82274502) （82074258,82274502）
第二批北京市研究型病房示范建设项目(BCRW202108) （BCRW202108）
中国中医科学院科技创新工程重大攻关项目(CI2021A01701) （CI2021A01701）
